TY - JOUR T1 - In vitro susceptibility of non-tuberculous mycobacterial strains against moxifloxacin JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P2645 AU - Timo Weiss AU - Nicolas Schönfeld AU - Thomas Bergmann AU - Harald Mauch AU - Torsten Blum AU - Holger Rüssmann AU - Torsten Thomas Bauer Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P2645.abstract N2 - IntroductionPulmonary infections due to non-tuberculous mycobacteria (NTM) are a clinical challenge. There are to date no recommendations for the use of potential second line drugs, when first line treatment failures. For Moxifloxacin, in vitro susceptibility could be shown for M. avium-komplex (MAC), but almost no data available on its in vitro effectivity against various other NTM species.MethodsFrom 100 NTM-positive cultures other than MAC isolated at our center during 2003-2010 (9 M. fortuitum, 2 M. chelonae, 6 M. gordonae, 5 M. marinum and 78 M. kansasii), we tested the minimal inhibitory concentrations (MIC) of moxifloxacin and thus the sensitivity(breakpoint ≤ 2 µg/ml). Culturing and resistance testing was performed on solid Middlebrook agar plates (7H11) by agar dilution.ResultsOut of 100 tested NTM-positive cultures, 98 (98%) showed sensitivity to moxifloxacin at. Only two strains (M. fortuitum and M. chelonae) showed higher MIC.ConclusionsOur study revealed a high sensitivity rate of moxifloxacin against several NTM strains other than MAC in vitro. Despite the absence of clinical treatment studies, we see a potential use of moxifloxacin as a second line drug. ER -